+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Human prolactin receptor variants in breast cancer: low ratio of short forms to the long-form human prolactin receptor associated with mammary carcinoma



Human prolactin receptor variants in breast cancer: low ratio of short forms to the long-form human prolactin receptor associated with mammary carcinoma



Cancer Research 64(16): 5677-5682



Prolactin plays an essential role in the development of rodent mammary tumors and is a potent mitogen in human normal and cancerous breast tissues/cells. In this study, we have analyzed the expression of prolactin receptors, including the long receptor form (LF; stimulatory) and two novel short forms (SFs; S1a and S1b) derived from alternative splicing that are inhibitory of the activation induced by prolactin through the LF. Southern analysis of breast cancer profiling arrays revealed that 29 patients (group I) expressed an elevated LF, 10 patients (group II) showed decreased LF, and 8 patients (group III) had no change relative to the adjacent normal tissue. Their respective SF expression was increased in 21 patients of group I and generally decreased in groups II and III. However, the ratio of SF to LF was significantly decreased in 76% of the breast tumors and distributed evenly among the groups. Quantification of differential expression of prolactin receptor variants by real-time PCR in 15 pairs of human normal and tumor breast-matched tissues revealed a similar significant decrease in the ratio of SF to LF in the tumor tissue. Consistent lower ratio of SFs to LFs was confirmed in 8 of ten different breast cancer cell lines compared with normal mammary Hs578Bst and MCF10A cells. Because SFs act as dominant negative regulators of the stimulatory actions of the LF in vitro, their relatively reduced expression in cancer could cause gradations of unopposed prolactin-mediated LF stimulatory function and contribute to breast tumor development/progression.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012160826

Download citation: RISBibTeXText

PMID: 15313907

DOI: 10.1158/0008-5472.can-04-1019


Related references

Impact of subdomain D1 of the short form S1b of the human prolactin receptor on its inhibitory action on the function of the long form of the receptor induced by prolactin. Biochimica et Biophysica Acta 1840(7): 2272-2280, 2014

Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 88(1): 69-77, 2004

Sequence and functional characterisation of the marmoset monkey (Callithrix jacchus) prolactin receptor: Comparative homology with the human long-form prolactin receptor. Molecular and Cellular Endocrinology 167(1-2): 89-97, 2000

S179D prolactin increases vitamin D receptor and p21 through up-regulation of short 1b prolactin receptor in human prostate cancer cells. Cancer Research 65(16): 7509-7515, 2005

Identification of a cDNA encoding a long form of prolactin receptor in human hepatoma and breast cancer cells. Molecular Endocrinology 3(9): 1455-1461, 1989

Short form 1b human prolactin receptor down-regulates expression of the long form. Journal of Molecular Endocrinology 44(3): 187-194, 2010

Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. American Journal of Pathology 146(3): 695-705, 1995

Prolactin-dependent growth and gamma-casein gene expression in Ba/F3 cells transfected with a long form of mouse mammary prolactin receptor. Endocrine Journal 43(1): 45-52, 1996

Comparison of long and short forms of the prolactin receptor on prolactin induced milk protein gene transcription. Proceedings of the National Academy of Sciences of the United States of America 88(3): 824-828, 1991

Role of prolactin/prolactin receptor signaling in human breast cancer. Breast Disease 18: 75-86, 2003

Novel reagents for human prolactin research: large-scale preparation and characterization of prolactin receptor extracellular domain, non-pegylated and pegylated prolactin and prolactin receptor antagonist. Protein Engineering Design and Selection 31(1): 7-16, 2018

Ligand-independent homo- and heterodimerization of human prolactin receptor variants: inhibitory action of the short forms by heterodimerization. Molecular Endocrinology 20(8): 1912-1923, 2006

Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments. Journal of Applied Toxicology 25(3): 179-183, 2005

Prolactin receptor in human mammary carcinoma. Tumori 65(6): 695-702, 1979

Intramolecular disulfide bonds of the prolactin receptor short form are required for its inhibitory action on the function of the long form of the receptor. Molecular and Cellular Biology 29(10): 2546-2555, 2009